These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 19954286)
1. What is new in kidney cancer? Kirkali Z Expert Rev Anticancer Ther; 2009 Dec; 9(12):1753-5. PubMed ID: 19954286 [TBL] [Abstract][Full Text] [Related]
2. Treatment of metastatic renal cell carcinoma. Reeves DJ; Liu CY Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348 [TBL] [Abstract][Full Text] [Related]
3. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents. Köpke T; Bierer S; Wülfing C; Tiemann A; Hertle L; Herrmann E Expert Rev Anticancer Ther; 2009 Jun; 9(6):763-71. PubMed ID: 19496713 [TBL] [Abstract][Full Text] [Related]
5. New therapeutic developments in renal cell cancer. Prenen H; Gil T; Awada A Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971 [TBL] [Abstract][Full Text] [Related]
6. New drug therapies for advanced renal cell carcinoma. Gore ME; Harrison ML; Montes A Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520 [TBL] [Abstract][Full Text] [Related]
7. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Ainsworth NL; Lee JS; Eisen T Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291 [TBL] [Abstract][Full Text] [Related]
12. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707 [TBL] [Abstract][Full Text] [Related]
13. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Polcari AJ; Gorbonos A; Milner JE; Flanigan RC Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114 [TBL] [Abstract][Full Text] [Related]